X
30.64
-2.91 (-8.67%)
| 前收盘价格 | 33.55 |
| 收盘价格 | 33.57 |
| 成交量 | 1,095,883 |
| 平均成交量 (3个月) | 449,290 |
| 市值 | 2,345,271,296 |
| 股市价格/股市净资产 (P/B) | 3.61 |
| 52周波幅 | |
| 利润日期 | 7 May 2025 - 12 May 2025 |
| 稀释每股收益 (EPS TTM) | -3.01 |
| 总债务/股东权益 (D/E MRQ) | 1.19% |
| 流动比率 (MRQ) | 17.85 |
| 营业现金流 (OCF TTM) | -181.39 M |
| 杠杆自由现金流 (LFCF TTM) | -117.59 M |
| 资产报酬率 (ROA TTM) | -19.80% |
| 股东权益报酬率 (ROE TTM) | -27.85% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Xenon Pharmaceuticals Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.9
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | 5.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 平均 | 1.88 |
|
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Core |
| 内部持股比例 | 0.37% |
| 机构持股比例 | 103.63% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 67.00 (Deutsche Bank, 118.67%) | 购买 |
| 中 | 60.00 (95.82%) | |
| 低 | 53.00 (HC Wainwright & Co., 72.98%) | 购买 |
| 平均值 | 60.00 (95.82%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 38.38 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 24 Feb 2025 | 53.00 (72.98%) | 购买 | 38.37 |
| Deutsche Bank | 11 Feb 2025 | 67.00 (118.67%) | 购买 | 38.39 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 12 Mar 2025 | 公告 | Xenon to Present at Stifel 2025 Virtual CNS Forum |
| 27 Feb 2025 | 公告 | Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update |
| 25 Feb 2025 | 公告 | Xenon to Present at the 45th Annual TD Cowen Healthcare Conference |
| 20 Feb 2025 | 公告 | Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025 |
| 13 Jan 2025 | 公告 | Xenon Outlines Key Corporate Milestone Opportunities for 2025 |
| 07 Jan 2025 | 公告 | Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合